Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress
Vishnu Chintalgattu, … , Mark L. Entman, Aarif Y. Khakoo
Vishnu Chintalgattu, … , Mark L. Entman, Aarif Y. Khakoo
Published January 11, 2010
Citation Information: J Clin Invest. 2010;120(2):472-484. https://doi.org/10.1172/JCI39434.
View: Text | PDF
Research Article Cardiology

Cardiomyocyte PDGFR-β signaling is an essential component of the mouse cardiac response to load-induced stress

  • Text
  • PDF
Abstract

PDGFR is an important target for novel anticancer therapeutics because it is overexpressed in a wide variety of malignancies. Recently, however, several anticancer drugs that inhibit PDGFR signaling have been associated with clinical heart failure. Understanding this effect of PDGFR inhibitors has been difficult because the role of PDGFR signaling in the heart remains largely unexplored. As described herein, we have found that PDGFR-β expression and activation increase dramatically in the hearts of mice exposed to load-induced cardiac stress. In mice in which Pdgfrb was knocked out in the heart in development or in adulthood, exposure to load-induced stress resulted in cardiac dysfunction and heart failure. Mechanistically, we showed that cardiomyocyte PDGFR-β signaling plays a vital role in stress-induced cardiac angiogenesis. Specifically, we demonstrated that cardiomyocyte PDGFR-β was an essential upstream regulator of the stress-induced paracrine angiogenic capacity (the angiogenic potential) of cardiomyocytes. These results demonstrate that cardiomyocyte PDGFR-β is a regulator of the compensatory cardiac response to pressure overload–induced stress. Furthermore, our findings may provide insights into the mechanism of cardiotoxicity due to anticancer PDGFR inhibitors.

Authors

Vishnu Chintalgattu, Di Ai, Robert R. Langley, Jianhu Zhang, James A. Bankson, Tiffany L. Shih, Anilkumar K. Reddy, Kevin R. Coombes, Iyad N. Daher, Shibani Pati, Shalin S. Patel, Jennifer S. Pocius, George E. Taffet, L. Maximillian Buja, Mark L. Entman, Aarif Y. Khakoo

×

Figure 3

Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart failure in response to pressure overload.

Options: View larger image (or click on image) Download as PowerPoint
Inducible, cardiac-specific PDGFR-β–knockout mice develop severe heart f...
(A) Expression of PDGFR-β in hearts from α-MHC-MerCreMer:Pdgfrbfl/fl mice (inducible, cardiac-specific PDGFR-β–knockout mice, PdgfrbMerCre) or Pdgfrbfl/fl controls harvested 7 days after exposure to tamoxifen. Results are representative of 4 independent hearts assessed from each group. (B) Ratio of right/left peak carotid velocity 24 hours after 8- to 12-week-old PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice were exposed to TAC. All groups of mice were treated with tamoxifen in an identical manner prior to baseline analysis and exposure to TAC stress (see Methods). (C) Heart weight/body weight ratios in 8- to 12-week-old PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice after TAC. (D) Cardiac ejection fraction of PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice prior to TAC or at time points after TAC, as measured by MRI. (E) LV end diastolic volume of PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice 14 days after TAC. (F) Representative hearts from Pdgfrbfl/fl or PdgfrbMerCre mice 14 days after TAC. (G) Expression levels of BNP assessed from mRNA from hearts of Pdgfrbfl/fl or PdgfrbMerCre mice prior to TAC or at time points after TAC (n = 4 samples per group at each time point). (H) Ratio of lung weight/body weight of PdgfrbMerCre, MerCreMer, or Pdgfrbfl/fl mice at baseline or at time points after TAC. P values were determined by ANOVA, and significant differences between PdgfrbMerCre and control (MerCreMer and Pdgfrbfl/fl) mice were confirmed with Tukey’s test. Numbers inside the bars indicate the number of animals analyzed.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts